New request system is intended to boost FDA transparency, allow patients to more easily gain access to agency staff.
The US FDA is taking a deliberately non-rigorous approach to one of its new data-gathering efforts – the a new online meeting request system for patients and other non-industry stakeholders to interact with staff.
John Whyte, director of Center for Drug Evaluation and Research's Professional Affairs and Stakeholder Engagement (PASE) staff said during an...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
